Grigory Ryzhakov
Novartis (Switzerland)(CH)University of Oxford(GB)
Publications by Year
Research Areas
interferon and immune responses, Cytokine Signaling Pathways and Interactions, Immune Response and Inflammation, NF-κB Signaling Pathways, Inflammatory Bowel Disease
Most-Cited Works
- → The TBK1 adaptor and autophagy receptor NDP52 restricts the proliferation of ubiquitin-coated bacteria(2009)851 cited
- → Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor–neutralizing therapy in patients with inflammatory bowel disease(2017)772 cited
- → SINTBAD, a novel component of innate antiviral immunity, shares a TBK1‐binding domain with NAP1 and TANK(2007)196 cited
- → Inhibition of IκB Kinase by Vaccinia Virus Virulence Factor B14(2008)153 cited
- → A Large Polysaccharide Produced by Helicobacter hepaticus Induces an Anti-inflammatory Gene Signature in Macrophages(2017)119 cited
- → IRF5 is required for late-phase TNF secretion by human dendritic cells(2010)96 cited
- → T6BP and NDP52 are myosin VI binding partners with potential roles in cytokine signalling and cell adhesion(2007)95 cited
- → IL-17 Boosts Proinflammatory Outcome of Antiviral Response in Human Cells(2011)87 cited
- → KAP1/TRIM28: An inhibitor of IRF5 function in inflammatory macrophages(2012)69 cited
- → Alpha kinase 1 controls intestinal inflammation by suppressing the IL-12/Th1 axis(2018)62 cited